title: A recombinant human interleukin-1 beta protects adriamycin-induced toxicity. Adriamycin cardiotoxicity and interleukin-1.
abstract: Pretreatment with recombinant human interleukin-1 beta (IL-1) protected normal BALB/c mice from the lethal effect adriamycin (ADM) of related to dose and frequency of administration. Posttreatment with IL-1 failed to protect. Neutrophil and platelet counts after the administration of ADM (16 mg/kg) did not differ between the group with and that without IL-1 pretreatment, whereas lipid peroxide levels in the heart were reduced in the group pretreated with IL-1. It appears that the chemoprotection mechanism of IL-1 lies in the prevention of cardiotoxicity due to ADM-induced free radicals.
authors: Department of Internal Medicine, Toyama Prefectural Central Hospital, Japan.
authors: H
authors: H
authors: Okumura
authors: T
authors: T
authors: Yoshida
authors: H
authors: H
authors: Kaya
authors: S
authors: S
authors: Matano
authors: Y
authors: Y
authors: Okabe
authors: S
authors: S
authors: Ohtake
authors: S
authors: S
authors: Nakamura
authors: T
authors: T
authors: Matsuda
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity*; D006321:Heart / Q000187:drug effects*; D007375:Interleukin-1 / Q000494:pharmacology*; D007958:Leukocyte Count / Q000187:drug effects; D008054:Lipid Peroxides / Q000032:analysis; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011994:Recombinant Proteins / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000096:biosynthesis
chemical_list: D007375:Interleukin-1; D008054:Lipid Peroxides; D011994:Recombinant Proteins; D004317:Doxorubicin; D013482:Superoxide Dismutase